EUCTR2020-006102-23-IT进行中（未招募）1 期
Study of a novel combination of immunovirologic and genetic parameters in early-treated HIV-1 patients undergone to antiretroviral therapy interruption (ATI) aimed at defining an algorithm predictive of post-treatment control (PCT) - ImmuneRaRe_RF-2019-12369708
OSPEDALE SAN RAFFAELE0 个研究点目标入组 100 人开始时间: 2021年6月7日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female, aged 18-60 years
- •Confirmed HIV-1 seropositivedocumented
- •ARTcommenced duringprimary HIV infection, as defined by Fiebig stage
- •Plasma HIV-RNA <50 copies/ml for at least 24 months
- •CD4+ T cell count > 350 cells/mm3 at the last routine follow-up visit
- •No new AIDS-defining diagnosis or progression of HIV-related disease
- •Able to adhere to an effective ART regimen for the duration of the study
- •Willing and able to give written informed consent for participation in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Confirmed HIV-2 seropositive
- •Women who are pregnant
- •History of systemic cancer, such as Kaposi’s sarcoma and lymphoma, or other virus-associated malignancies and/or history of AIDS-defining illness according to Centers for Disease Control and Prevention criteria
- •Active or chronic hepatitis B virus infection, with detectable hepatitis B surface antigen, hepatitis B virus DNA, or both active and chronic hepatitis C virus infection, with detectable virus RNA, and syphilis
- •Naso-pharyngeal swab positive for SARS-CoV-2
研究者
相似试验
进行中（未招募）
1 期
Study of the genetic, viral and immune response characteristics of a group of patients infected with the AIDS virus treated early and then subjected to suspension of antiretroviral therapy to define biological markers predicting the control of virus replication after pharmacological treatmentCTIS2024-515419-24-00Ospedale San Raffaele S.r.l.100
尚未招募
不适用
An integrated immunological-pharmacological approach to improve long-term allograft functiograft failurekidney transplantation10029149NL-OMON45414Inwendige Geneeskunde - Nefrologie en Transplantatie420
招募中
2 期
Combined sublingual immunotherapy VALERGEN-DP and VALERGEN-BT-Asthma-Adults-Phase IIAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessRPCEC00000240ational Center of Bioproducts (BIOCEN)120
已完成
1 期
A combination immunotherapy for the patients with advanced or metastatic solid cancersolid cancerJPRN-UMIN000020440Yamaguchi university Graduate School of Medicine17
进行中（未招募）
不适用
Pilot phase II study of a combined immunotherapy protocol based on oral vaccination and direct intratumoral injection of Salmonella Typhi Ty21a Vivotif in metastatic cutaneous melanoma patients. - NDMetastatic stage III e IV M1a melanomaMedDRA version: 6.1Level: PTClassification code 10042551EUCTR2005-005775-15-ITISTITUTO EUROPEO DI ONCOLOGIA43